Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of emergency was declared in Japan, as had been by other nations worldwide. This unprecedented crisis has profound implications for patients undergoing chemotherapy and for practicing healthcare professionals. Various reports have shown data indicating that cancer patients with COVID-19 have high morbidity and mortality rates. In order to reduce the use of medical resources to avoid the risk of COVID-19 infections in both cancer patients and health care providers, oncologists now have to draw the line for cancer treatments by maintaining their efficacy while avoiding severe adverse events. In this article, we outlined the decisions made regarding the practice of gastrointestinal oncology in our institution during the COVID pandemic.
【저자키워드】 COVID-19, Chemotherapy, Gastrointestinal oncology, 【초록키워드】 Coronavirus disease 2019, Efficacy, pandemic, healthcare professionals, Infection, COVID, global pandemic, Health, oncology, Patient, Japan, morbidity and mortality, Care, cancer treatment, cancer patient, World Health Organization, severe adverse events, implication, risk of COVID-19, oncologist, medical resource, shown, reduce, outlined, with COVID-19, 【제목키워드】 oncology, Japan, Japanese, foundation, managing,